【BIOHLDG 0179 交流专区】

icy97

Name	MR HON TIAN KOK @ WILLIAM
Descriptions(Class & nominal value)	Ordinary shares of RM0.05 each

Details of changes

Currency: Malaysian Ringgit (MYR)

Type of transaction	Date of change	No of securities	Price Transacted (RM)
Disposed	30/03/2016	11,500,000	0.440

Circumstances by reason of which change has occurred	Off market transaction
Nature of interest	Direct
Consideration (if any)

Total no of securities after change
Direct (units)	81,567,506
Direct (%)	16.314
Indirect/deemed interest (units)	0
Indirect/deemed interest (%)	0.000
Date of notice	30/03/2016

icy97

Name	PERBADANAN NASIONAL BERHAD
Address	Level 16, Menara PNS Tower 7 Avenue 7, Bangsar South City No. 8, Jalan Kerinchi Kuala Lumpur 59200 Wilayah Persekutuan Malaysia.
Company No.	9157-K
Nationality/Country of incorporation	Malaysia
Descriptions (Class & nominal value)	Ordinary shares of RM0.05 each
Name & address of registered holder	Perbadanan Nasional Berhad Level 16, Menara PNS Tower 7Avenue 7, Bangsar South CityNo. 8, Jalan Kerinchi59200 Kuala LumpurWilayah Persekutuan

Details of changes

Currency: Malaysian Ringgit (MYR)

Type of transaction	Description of Others	Date of change	No of securities	Price Transacted (RM)
Disposed		03 May 2016	18,751,502

Circumstances by reason of which change has occurred	Off market transaction
Nature of interest	Direct
Direct (units)	51,566,629
Direct (%)	10.313
Indirect/deemed interest (units)	0
Indirect/deemed interest (%)	0
Total no of securities after change	51,566,629
Date of notice	04 May 2016

icy97

Type	Announcement
Subject	OTHERS
Description	BIOALPHA HOLDINGS BERHAD- ACQUISITION OF AN INDIRECT SUBSIDIARY OF THE COMPANY
1. Introduction The Board of Directors of Bioalpha Holdings Berhad (“Bioalpha” or “the Company”) wishes to announce that Bioalpha International Sdn. Bhd. (715156-K) (“BISB”), the wholly-owned subsidiary of the Company had acquired a 60% stake/ equity in PT. Herbal Malindo Makmur (“PT. HMM”) in Indonesia on 4 May 2016. 2. Details of PT. Herbal Malindo Makmur and purpose for the acquisition PT. HMM is a company incorporated in Indonesia with an authorised and paid up capital of USD250,000/-. PT. HMM’s intended principal activity is manufacturing of health supplement products. BISB holds 60% of the share capital of PT. HMM whereas the balance of 40% is held by the following party:- No. Name (Nationality) Amount in USD Percentage (%) 1. Mutia Restiana 100,000 40% The legal representative of PT. HMM is Mr. Hon Tian Kok @ William who is the Managing Director/ Chief Executive Officer of Bioalpha. 3. Consideration The investment in the share capital of PT. HMM and its acquisition expenses are financed by internally generated funds. 4. Effects of the acquisition of PT. HMM The acquisition of PT. HMM does not have any effect on the issued and paid up capital of the Company and the Substantial Shareholders’ Shareholding. The acquisition also does not have no material effect on earnings per share nor net assets per share of Bioalpha and its Group for year ending 31 December 2016. 5. Approval from Authorities The Acquisition is not subject to the approval of the shareholders of the Company or other relevant authorities. 6. Directors’ and Major Shareholders’ Interests Save for Mr. Hon Tian Kok @ William who was the subscriber of PT. HMM, none of the directors and/or major shareholders of the Company and/or persons connected with them has any interest, direct or indirect in the Acquisition. 7. Statement by Directors The Board of Directors of the Company is of the opinion that the establishment of PT. HMM is in the best interest of the Bioalpha Group. This announcement is dated 4 May 2016.

pts2222

印尼业务受看好 科鼎反弹走高
By Tan Siew Mung / theedgemarkets.com   | May 6, 2016 : 12:26 PM MYT   
http://www.theedgemarkets.com/my/article/印尼业务受看好-科鼎反弹走高

（吉隆坡6日讯）科鼎（Bioalpha Holdings Bhd）今早一度反弹7.25%，此前联昌国际投资银行研究指，印尼业务可能提振该公司未来两年的盈利。

这家综合保健品生产商由3月29日的45仙（52周新高），下跌超过23%，至昨日的34.5仙。

今日在强劲买盘推动，收复部分失地。

该股最高扬2.5仙，至37仙，截至12时02分报36.5仙，起2仙或5.8%，成交量有1193万7600股，是主要热门股之一。

联昌国际研究今日在报告指出，印尼业务未来两年的增长可能快于20%的年营业额增长预测。

“假设该公司在2017年销售20样产品，以及印尼的收入在2017及2018年年增50%，我们的2017和2018财年的每股盈利预测将分别上调9和18%。”

印尼市场是最大的收入来源，接近集团营业额的一半。

该公司周三宣布，已收购印尼 PT Herbal Malindo Makmur的60%股权。

PT Herbal Malindo Makmur预期的主要业务是药材加工和生产科鼎的保健产品。

联昌国际视新厂房设立为正面惊喜，因缩短新产品的注册期，从2年至6个月。

该机构重申“加码”评级，并认为该股是消费小型股的首选。这是基于2017年25倍本益比目标折价20%。

（编译：陈慧珊）


科鼎印尼买公司展拳脚
财经新闻 财经  2016-05-14 11:17
http://www.nanyang.com/node/761276?tid=462

icy97

Type	Announcement
Subject	TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS) RELATED PARTY TRANSACTIONS
Description	BIOALPHA HOLDINGS BERHAD - ACQUISITION OF AN INDIRECT SUBSIDIARY OF THE COMPANY
Reference is made to the Company’s announcement made on 4 May 2016. The Board of Directors of Bioalpha Holdings Berhad (“Bioalpha” or “the Company”) wishes to further announce on the followings:- 1. Mr. Hon Tian Kok @ William, who is the Managing Director/ Chief Executive Officer of Bioalpha, had on behalf of the Company agreed to subscribe 150,000 shares in PT. HMM, representing 60% of the total paid up capital of PT.HMM (“Subscriber Shares”). Thereafter, the right to subscription of 150,000 shares in PT. HMM has been transferred to Bioalpha International Sdn. Bhd. (715156-K), a wholly-owned subsidiary of the Company on 4 May 2016 (“Acquisition”) at no cost. 2. The total cost of investment to be incurred by the Company for subscription of 150,000 shares in PT.HMM is amounting to USD150,000 or equivalent to approximately RM600,000.00 and will be fully satisfied by cash via internally generated funds. Full payment is expected to be made by the second quarter of 2016. 3. The total cost of investment of USD150,000 is derived from its nominal value of one (1) share at USD1 each. 4. The highest percentage ratio applicable to the Acquisition pursuant to Rule 10.02(g) of the Listing Requirements is 0.76%. This announcement is dated 11 May 2016.

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31 Mar 2016

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31 Mar 2016	31 Mar 2015	31 Mar 2016	31 Mar 2015
		$$'000	$$'000	$$'000	$$'000

1	Revenue	6,908	3,226	6,908	3,226
2	Profit/(loss) before tax	34	14	34	14
3	Profit/(loss) for the period	11	-29	11	-29
4	Profit/(loss) attributable to ordinary equity holders of the parent	122	14	122	14
5	Basic earnings/(loss) per share (Subunit)	0.03	0.00	0.03	0.00
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.1793		0.1705

icy97

Type	Announcement
Subject	MULTIPLE PROPOSALS
Description	BIOALPHA HOLDINGS BERHAD ("BIOALPHA" OR THE "COMPANY")(I) PROPOSED BONUS ISSUE;(II) PROPOSED SHARE ISSUANCE SCHEME;(III) PROPOSED INCREASE IN AUTHORISED SHARE CAPITAL; AND(IV) PROPOSED AMENDMENT TO MEMORANDUM OF ASSOCIATION
On behalf of the Board of Directors of Bioalpha (“Board”), TA Securities Holdings Berhad (“TA Securities”) wishes to announce that the Company proposes to undertake the following: (i) proposed bonus issue of 166,666,666 new ordinary shares of RM0.05 each in the Company (“Bioalpha Shares”) (“Bonus Shares”) on the basis of one (1) Bonus Share for every three (3) existing Bioalpha Shares held at an entitlement date to be determined later (“Entitlement Date”) (“Proposed Bonus Issue”); (ii) proposed share issuance scheme of up to thirty percent (30%) of the Company’s issued and paid-up share capital (excluding any treasury shares) at any one time during the duration of the scheme for the eligible Directors and employees of Bioalpha group of companies (“Bioalpha Group” or “Group”) (excluding dormant subsidiaries) (“Proposed SIS”); (iii) proposed increase in the authorised share capital of Bioalpha from RM25,000,000 comprising 500,000,000 Bioalpha Shares to RM100,000,000 comprising 2,000,000,000 Bioalpha Shares (“Proposed Increase in Authorised Share Capital”); and (iv) proposed amendment to the Memorandum of Association (“MOA”) of Bioalpha to facilitate the Proposed Increase in Authorised Share Capital (“Proposed MOA Amendment”). (collectively referred to as the “Proposals”) Further details on the Proposals are set out in the attachment. This announcement is dated 27 May 2016.

http://www.bursamalaysia.com/market/listed-companies/company-announcements/5107621

Attachments Bioalpha - Proposals.pdf

icy97

廖内省厂房明年营运
科鼎看好印尼业务倍增

2016年6月3日
（吉隆坡2日讯）科鼎（BIOHLDG，0179，创业板）看好印尼业务营业额，可在明年倍增。

根据文告，科鼎位于廖内省的厂房，将在今年第三季开始营运，从而加速新产品的推出。

董事经理兼总执行长韩丁国指出，公司目前正把产品出口到印尼，但相关产品在当地注册的程序，需时长达2年，拖慢公司推介更多产品的步伐。

因此，公司如今在印尼拥有厂房，有助把产品注册时间，缩短至6个月。

他说：“虽然目前印尼业务只有10种产品，但公司在当地的销售表现依然相当亮眼，每年平均取得30%的增长率。”

展望未来，一旦厂房投入运作，韩丁国看好公司潜能可获提升，并有能力在数个月内，推出更多新产品，以吸引和留住客户。

印尼占50%营业额

“在2015财年，印尼是我们最大的出口市场，且贡献了接近50%的营业额。”

此外，科鼎也放眼通过自家零售药房，展开促销活动，来加强国内销售。

韩丁国点出，公司与MyAngkasa控股的联营计划，也可推动药房业务的扩展计划。

科鼎属于综合保健品生产业者，主要业务是生产、销售原厂设计制造（ODM）及自家保养品品牌。【e南洋】

icy97

科鼎靠印尼中国推营收

2016年7月6日
（万宜5日讯）科鼎（BIOHLDG，0179，创业板）指出，借助对印尼与中国市场的出口业务，推动未来两年的营业额增长。

《星报》报道，董事经理兼总执行长韩丁国表示，印尼是该公司的核心市场，在过去5年内持续增加，年均复增达37%。

科鼎出产清真与非清真草药为基础的保健品，公司预计，印尼市场的营业额未来两年将增长50%。

他提及科鼎于今年5月收购印尼公司PT.Herbal Malindo Makmur（PT.HMM）的60%股权，不只解决了产品注册与重新包装的问题，也扩展了当地的市占率。

至于中国市场方面，需求量也日益增加，成为科鼎第二大出口市场，于2015财年占公司营业额的28%或830万令吉。

“我们会专注在穆斯林人口稠密区，如兰州、新疆、西安、青海，并且从这些省份找到了4家分销商。”

至于本地业务方面，该公司向来都会探讨以并购的方式，扩展药剂零售网络，同时有意在短期内采取连锁加盟模式。【e南洋】

icy97

印尼厂房投运推新产品‧科鼎出口业务驱动成长

（吉隆坡5日讯）保健品制造商科鼎控股（BIOHLDG，0179，创业板消费品组）印尼新厂房即将投运，并放眼印尼与中国将驱动业务成长，分析员预期该公司明年在印尼推出新产品后，盈利有望更快速成长。

联昌研究表示，科鼎控股接受媒体专访时表示，公司在印尼新厂将在8月投运，并预期出口业务将驱动公司未来两年成长，特别是印尼与中国的市场需求。

冀产品种类增至20个

该公司预期，印尼营业额未来2年可取得50%的成长。

印尼新厂面积达4000方尺，除了可解决产品注册问题，也可重新包装半完成品。过去印尼需要2至3年方才批准新产品销售，现在只需6个月。因此，管理层放眼2017年，将销售产品种类可增加至20个。目前，该公司在印尼只销售10种产品。

管理层披露，该公司在2015财政年第二季才涉足中国市场，但中国市场却贡献公司28%或830万令吉的营业额。该公司产品主攻中国穆斯林人口为主的地区，包括兰州、西安、新疆与青海。

科鼎控股在柔佛及登嘉楼拥有种植地库，面积分别为300及1000英亩。柔佛可收成的草药种类逾20种，而登嘉楼目前则只有123英亩为成熟地库，管理层说，余下地库成熟期预期为2020年，届时每年收成量达400吨。此外，科鼎控股也有13家药剂店——Constant，分布于巴生河流域一带，未来会以特许经营权方式经营，未来将会把药剂店拓展至吉兰丹。

联昌研究指出，该公司近期建议派送红股，比例3送1，股本从5亿股提高至6亿6700万股，此举有助于提升股票流通量，有关建议已经提呈当局批准。

联昌维持该公司“买进”评级与65仙目标价不变，这是根据该公司2017财政年的本益比20倍估值，低于消费领域的25倍本益比，此折价反映其小资本股地位。

文章来源：
星洲日报‧财经‧报道：谢汪潮‧2016.07.06


科鼎中印业务齐护航
2016年7月9日
http://www.enanyang.my/news/20160709/科鼎中印业务齐护航/

icy97

科鼎印尼厂9月营运
第三季贡献盈利

2016年8月20日
（吉隆坡19日讯）科鼎（BIOHLDG，0179，创业板）位于印尼苏门答腊岛廖内省坎帕（Kampar）工厂的建设和装修工程竣工，预计在9月初开始营运，并为第三季财年贡献盈利。

根据文告，科鼎在印尼设立工厂是一项战略举措，将缓解过去推出新产品时所面对耗时的问题，并增强印尼科鼎的销售量，因为印尼生产与从外国进口的产品，注册过程分别为几个月以及两年左右。

目前，印尼是科鼎的最大市场，为公司贡献1440万令吉盈利，或相等于2015财年近一半的盈利。

科鼎董事经理韩丁国说：“我们的产品还不到10种，就取得1440万令吉成绩，相信新厂运作后，印尼销售量会保持双位数增长，而我们也将在接下来的两年推出12种新产品。”

工厂的第一阶段2条生产线，制造香囊与茶袋包装，估计12个月内达到最佳产量，第二阶段添加2条生产线，封装和制作药片。

“我们已分划目标客户群，从地方当局申请更多执照，以实惠价格获得当地草药成分，扩展产品多样性。”【e南洋】

哭哭鸟

SUMMARY OF KEY FINANCIAL INFORMATION 30 Jun 2016

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30 Jun 2016	30 Jun 2015	30 Jun 2016	30 Jun 2015
		$$'000	$$'000	$$'000	$$'000

1	Revenue	11,966	8,252	18,874	11,479
2	Profit/(loss) before tax	1,379	499	1,413	513
3	Profit/(loss) for the period	1,284	225	1,295	196
4	Profit/(loss) attributable to ordinary equity holders of the parent	1,395	396	1,518	410
5	Basic earnings/(loss) per share (Subunit)	0.28	0.09	0.31	0.10
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.1821		0.1705

icy97

BIOALPHA HOLDINGS BERHAD

EX-date	07 Sep 2016
Entitlement date	09 Sep 2016
Entitlement time	05:00 PM
Entitlement subject	Bonus Issue
Entitlement description	Bonus issue of 166,666,666 new ordinary shares of RM0.05 each in Bioalpha Holdings Berhad ("Bioalpha") ("Bioalpha Shares") ("Bonus Shares") on the basis of one (1) Bonus Share for every three (3) existing Bioalpha Shares ("Bonus Issue")
Period of interest payment	to
Financial Year End
Share transfer book & register of members will be	to   closed from (both dates inclusive) for the purpose of determining the entitlement
Registrar or Service Provider name, address, telephone no	SYMPHONY SHARE REGISTRARS SDN BHDLevel 6, Symphony HousePusat Dagangan Dana 1Jalan PJU 1A/4647301Petaling JayaTel:0378490777Fax:0378418151
Payment date
a.Securities transferred into the Depositor's Securities Account before 4:00 pm in respect of transfers	09 Sep 2016
b.Securities deposited into the Depositor's Securities Account before 12:30 pm in respect of securities exempted from mandatory deposit
c. Securities bought on the Exchange on a cum entitlement basis according to the Rules of the Exchange.
Number of new shares/securities issued (units) (If applicable)
Entitlement indicator	Ratio
Ratio	1 : 3
Rights Issue/Offer Price
Par Value	Malaysian Ringgit (MYR) 0.050

icy97

Date of change	30 Aug 2016
Name	DATO' SRI SYED ZAINAL ABIDIN BIN SYED MOHAMED TAHIR
Age	54
Gender	Male
Nationality	Malaysia
Designation	Executive Director
Directorate	Executive
Type of change	Resignation
Reason	Personal Commitment
Details of any disagreement that he/she has with the Board of Directors	No
Whether there are any matters that need to be brought to the attention of shareholders	No
Qualifications
Working experience and occupation
Family relationship with any director and/or major shareholder of the listed issuer	Nil
Any conflict of interests that he/she has with the listed issuer	Nil
Details of any interest in the securities of the listed issuer or its subsidiaries	1,620,769 ordinary shares

icy97

5配1附加股送凭单
科鼎拟筹2800万

2016年9月8日
（吉隆坡7日讯）科鼎（BIOHLDG，0179，创业板）建议，以每5股配1股附加股送1凭单比例，发出1亿3333万3333股新股和相同数额的凭单。

假设附加股的发售价为每股21仙，则该批附加股预计可筹得约2800万令吉。其中，1350万令吉将用来推介新产品、1000万令吉用来拓展农业业务、以及350万令吉作为资本开销。

目前，科鼎的三个主要市场别为大马、印尼和中国。

该公司预计，这些市场的保健品需求正处于上升趋势，因此有意在三个市场推出新产品，以提升获利能力，并夺取更大的市占率。【e南洋】

Type	Announcement
Subject	NEW ISSUE OF SECURITIES (CHAPTER 6 OF LISTING REQUIREMENTS) FUND RAISING
Description	BIOALPHA HOLDINGS BERHAD ("BIOALPHA" OR THE "COMPANY")PROPOSED RENOUNCEABLE RIGHTS ISSUE OF 133,333,333 NEW ORDINARY SHARES OF RM0.05 EACH IN BIOALPHA ("BIOALPHA SHARE(S)") ("RIGHTS SHARE(S)") TOGETHER WITH 133,333,333 FREE NEW DETACHABLE WARRANTS ("WARRANTS") AT AN ISSUE PRICE TO BE DETERMINED LATER ON THE BASIS OF 1 RIGHTS SHARE FOR EVERY 5 BIOALPHA SHARES HELD TOGETHER WITH 1 WARRANT FOR EVERY 1 RIGHTS SHARE SUBSCRIBED ("PROPOSED RIGHTS ISSUE WITH WARRANTS")
On behalf of the Board of Directors of Bioalpha (“Board”), Hong Leong Investment Bank Berhad (“HLIB”) wishes to announce that Bioalpha proposes to undertake a renounceable rights issue of 133,333,333 new ordinary shares of RM0.05 each in Bioalpha (“Bioalpha Share(s)”) (“Rights Share(s)”) together with 133,333,333 free new detachable warrants (“Warrants”) on the basis of 1 Rights Share for every 5 Bioalpha Shares held together with 1 Warrant for every Rights Share subscribed by the existing shareholders of Bioalpha on an entitlement date to be determined by the Board and announced later (“Proposed Rights Issue with Warrants”). Please refer to the attachment for further details on the Proposed Rights Issue with Warrants.

http://www.bursamalaysia.com/market/listed-companies/company-announcements/5200617

Attachments Bioalpha - Proposed Rights Issue with Warrants.pdf

icy97

科鼎
送凭单筹2800万

2016年9月9日

分析：联昌国际投行研究
目标价：52仙

最新进展

科鼎（BIOHLDG，0179，创业板）建议，以每5股配1股附加股送1凭单比例，发出1亿3333万3333股新股和相同数额的凭单。

假设附加股的发售价为每股21仙，公司预计可筹得约2800万令吉。

其中，1350万令吉用来推介新产品、1000万令吉用来拓展农业业务，350万令吉作为资本开销。

行家建议

我们对于科鼎的附加股计划感到正面，因为所筹集的资金，会用在：1）在Pasir Raja栽种草药，占地880英亩；2）购买新原料、包装成本，及新产品的营运资本。

科鼎在未来几个月，将在旗下所有市场（中国、印尼、马来西亚）推出新产品。

另外，科鼎早前3送1红股已在7日除权，股本也从5亿股增至6.67亿股，可改善股票流通率，较低的股价也可吸引散户。红股除权后经调整的目标价为52仙。

至于附加股，21仙认购价相等于红股除权后目标价52仙的折价25%，我们认为合理，因为股东同时也获增凭单。

在纳入红股及附加股计划后，科鼎的股本进一步增加至9.34亿股，估计2017财年每股净利将被稀释35%，而我们的目标价也进一步调整至37仙。



【e南洋】

icy97

Type	Announcement
Subject	NEW ISSUE OF SECURITIES (CHAPTER 6 OF LISTING REQUIREMENTS) FUND RAISING
Description	BIOALPHA HOLDINGS BERHAD ("BIOALPHA" OR THE "COMPANY")PROPOSED RENOUNCEABLE RIGHTS ISSUE OF 133,333,131 NEW ORDINARY SHARES OF RM0.05 EACH IN BIOALPHA ("BIOALPHA SHARE(S)") ("RIGHTS SHARE(S)") TOGETHER WITH 133,333,131 FREE NEW DETACHABLE WARRANTS ("WARRANTS") AT AN ISSUE PRICE TO BE DETERMINED LATER ON THE BASIS OF 1 RIGHTS SHARE FOR EVERY 5 BIOALPHA SHARES HELD TOGETHER WITH 1 WARRANT FOR EVERY 1 RIGHTS SHARE SUBSCRIBED ("PROPOSED RIGHTS ISSUE WITH WARRANTS")
Unless otherwise defined, the terms used in this announcement shall have the same meaning as those defined in the announcement dated 7 September 2016. Reference is made to the announcement dated 7 September 2016 in relation to the Proposed Rights Issue with Warrants. In addition, the Company had on 9 September 2016, announced that after disregarding fractional entitlements arising from the Bonus Issue, the total number of Bioalpha Shares to be listed on the ACE Market of Bursa Securities pursuant to the Bonus Issue on 13 September 2016 is 166,665,655 Bioalpha Shares. Consequently, on behalf of the Board, HLIB wishes to announce that after taking into consideration the enlarged issued and paid-up share capital of Bioalpha upon completion of the Bonus Issue which comprises of 666,665,655 Bioalpha Shares, the Proposed Rights Issue with Warrants of Bioalpha will now entail a renounceable rights issue of 133,333,131 Rights Shares together with 133,333,131 Warrants on the basis of 1 Rights Share for every 5 Bioalpha Shares held together with 1 Warrant for every Rights Share subscribed by the existing shareholders of Bioalpha on an entitlement date to be determined by the Board and announced later. Please refer to the attachment for further details on the Proposed Rights Issue with Warrants.

http://www.bursamalaysia.com/market/listed-companies/company-announcements/5208173

Attachments Bioalpha - Proposed Rights Issue with Warrants (Clarification Announcement_19.09.2016).pdf

icy97

科鼎业绩佳送红股．为什么股价不涨？

读者tay问：

创业板的科鼎控股（BIOHLDG，0179，创业板科技组）今年业绩都有明显的上涨，新闻也一直发布公司积极向上的扩充，公司也宣布派发红股，但股价却迟迟不上涨，公司是否有什么问题？是否还值得投资？

答：科鼎控股刚在9月7日的3送1红股计划除权当日，即在同日马上宣布发售附加股送凭单向股东筹资（5配1附加股送1凭单）。

股价不涨或因为发附加股

通常投资者或股东是不欢迎公司发售附加股筹资，因为他们又要掏腰包付钱给公司资金。相信这是抑制股价表现的个中原因。

你说得不错，该公司今年业绩有改善及正积极向上扩充业务，包括印尼市场在内。

公司是否有什么问题不得而知；不过，看看资产负债表探探它的财务情况。

截至2016年6月30日为止，该公司资产下的银行定期存款为697万5000令吉、现金及等同现金为699万2000令吉。

流动负债下的银行借贷仅为73万1000令吉、而非流动负债的银行借贷则为228万5000令吉。公司股本为2500万令吉、保留盈利为3795万8000令吉。每股资产值为18.21仙。

资料显示其财务情况还相当健全。

是否还值得投资，没有证券研究或分析员给予评估及建议。

文章来源：
星洲日报‧投资致富‧投资问诊‧文：李文龙‧2016.10.16

icy97

Type	Announcement
Subject	NEW ISSUE OF SECURITIES (CHAPTER 6 OF LISTING REQUIREMENTS) FUND RAISING
Description	BIOALPHA HOLDINGS BERHAD ("BIOALPHA" OR "COMPANY")RENOUNCEABLE RIGHTS ISSUE OF 133,333,131 NEW ORDINARY SHARES OF RM0.05 EACH IN BIOALPHA ("BIOALPHA SHARE(S)") ("RIGHTS SHARE(S)") TOGETHER WITH 133,333,131 FREE NEW DETACHABLE WARRANTS ("WARRANTS") AT AN ISSUE PRICE OF RM0.20 ON THE BASIS OF 1 RIGHTS SHARE FOR EVERY 5 BIOALPHA SHARES HELD TOGETHER WITH 1 WARRANT FOR EVERY 1 RIGHTS SHARE SUBSCRIBED ("RIGHTS ISSUE WITH WARRANTS")
Unless otherwise defined, the terms used in this announcement shall have the same meaning as those defined in the announcement dated 7 September 2016. We refer to the announcements dated 7 September 2016, 19 September 2016, 13 October 2016 and 15 November 2016 as well as the Circular to the shareholders of Bioalpha in relation to the Rights Issue with Warrants dated 31 October 2016. On behalf of the Board of Directors of Bioalpha, Hong Leong Investment Bank Berhad wishes to announce that the Board had, on even date, resolved to fix the Issue Price of the Rights Shares at RM0.20 per Rights Share and the Exercise Price of the Warrants at RM0.22 per Warrant. Basis and justifications of determining the Issue Price The Board had fixed the Issue Price after taking into consideration, amongst others, the following: (i)         The funding requirements of the Bioalpha Group; (ii)        The 5-day VWAMP of RM0.2352 per Bioalpha Share up to and including 17 November 2016, being the last trading day prior to the Price Fixing Date; (iii)        The minimum issue price allowable under the Act, which is not lesser than the par value of the Bioalpha Shares of RM0.05 each; and (iv)       The discount to the Issue Price of not more than 25% to the TERP of the Bioalpha Shares. The discount to the Issue Price was determined by the Board after taking into account the following: (i)         The funding requirements of our Group; (ii)        Bioalpha Shares were traded at the lowest of RM0.230 per Bioalpha Share and the highest of RM0.450 for the past 12 months up to and including 17 November 2016, being the last trading day prior to the Price Fixing Date; and (iii)        The discount will provide the existing shareholders with an attractive opportunity to further increase their equity participation in the Company at a discount to the prevailing market price of Bioalpha Shares. The Issue Price of RM0.20 per Rights Share represents a discount of approximately RM0.025 or 11.11% to the TERP of RM0.225 per Bioalpha Shares computed based on the 5-day VWAMP of Bioalpha Share up to and including 17 November 2016, being the last trading day prior to the Price Fixing Date. Basis and justifications of determining the Exercise Price The Board has fixed the Exercise Price after taking into consideration, amongst others, the following: (i)         The future prospects of the Bioalpha Group; (ii)        The 5-day VWAMP of RM0.2352 per Bioalpha Share up to and including 17 November 2016, being the last trading day prior to the Price Fixing Date; and (iii)        The minimum issue price allowable under the Act, which is not lesser than the par value of the Bioalpha Shares of RM0.05 each. The Exercise Price of RM0.22 per Warrant represents a discount of approximately RM0.005 or 2.22% to the TERP of RM0.225 per Bioalpha Shares computed based on the 5-day VWAMP of Bioalpha Share up to and including 17 November 2016, being the last trading day prior to the Price Fixing Date. This announcement is dated 18 November 2016.

哭哭鸟

SUMMARY OF KEY FINANCIAL INFORMATION 30 Sep 2016

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30 Sep 2016	30 Sep 2015	30 Sep 2016	30 Sep 2015
		$$'000	$$'000	$$'000	$$'000

1	Revenue	12,088	8,536	30,962	20,015
2	Profit/(loss) before tax	2,718	2,534	4,131	3,048
3	Profit/(loss) for the period	2,668	2,441	3,963	2,638
4	Profit/(loss) attributable to ordinary equity holders of the parent	2,782	2,552	4,300	2,963
5	Basic earnings/(loss) per share (Subunit)	0.54	0.55	0.85	0.70
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.1824		0.1705